Target intelligence / Profile preview

Bystin (BYSL)

Target
BYSL
Molecular classification
Other (ribosome biogenesis factor/protein involved in rRNA processing), Other (accessory protein for cell adhesion during embryo implantation)[2][4][6]
01

Overview

Bystin is a highly conserved, non-enzymatic protein encoded by the BYSL gene. It plays a dual role in mammalian cellular physiology: as an **essential ribosome biogenesis factor**, it facilitates the maturation of the small (40S) ribosomal subunit by supporting proper processing of 18S rRNA, thus supporting rapid cell growth and protein synthesis in proliferative contexts such as embryonic tissues and cancers[2][4][6]. In parallel, bystin mediates **cell adhesion processes** crucial for embryo implantation by forming complexes with trophinin and tastin, stabilized further by cytokeratin interactions[1][5]. BYSL is localized to the nucleolus and cytoplasm, its expression is regulated by growth signals (including c-MYC), and is highly expressed in dividing cells. Knockdown or loss leads to severe defects in cell viability, nucleologenesis, and embryo development. BYSL is not a typical therapeutic target (receptor, enzyme, transporter), but may serve as a proliferation marker, especially in cancers, and as a molecular link between cell adhesion and ribosomal function[1][2][3][4][6].

Other names
BYSTINENP1Enp1bystinbystin-likeBYSTENP1 homologby the ribosomal protein S6 gene Drosophila homolog-like
02

Biological functions

Ribosome biogenesis (required for processing 20S pre-rRNA and formation of the 40S ribosomal subunit)[2][4][6]Cell adhesion (via interaction with trophinin and tastin, important for trophoblast/embryo implantation)[1][4]Regulation of cell proliferation/differentiation (especially during early development and in rapidly dividing cells, such as cancer cells)[2][3][4]
03

Disease associations

Cancer (notably hepatocellular carcinoma and diffuse large B-cell lymphoma)[3][4]Pregnancy-related (roles in embryo implantation and abnormal expression in ectopic pregnancies)[1][4][5]Other (association with Juxtacortical Chondrosarcoma)[5]
04

Safety considerations

Loss of BYSL disrupts ribosomal biogenesis, impairs cell viability, and induces apoptosis[3][4]High expression correlates with malignancy and proliferation in certain cancers[3][4]
05

Biomarkers

BYSL expression as a possible biomarker for hepatocellular carcinoma[3]BYSL amplification in diffuse large B-cell lymphoma[4]

Beyond the preview

Go deeper on Bystin (BYSL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bystin (BYSL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call